REG - Genedrive PLC - Director/PDMR Shareholding

GenedriveAnnouncement

20/12/2024 12:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241220:nRST9735Qa&default-theme=true

RNS Number : 9735Q  Genedrive PLC  20 December 2024

genedrive plc

("genedrive" or the "Company")

 

Director/PDMR Notification

 

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company
announces that on 20 December 2024, Dr Ian Gilham, Non-Executive Chairman,
acquired 225,000 ordinary shares of 1.5p each ("Ordinary Shares") at 2.344p
per share, Dr Gino Miele, Chief Executive Officer, acquired 1,135,208 Ordinary
Shares in the Company at a price of 2.2p per share,  Russ Shaw, Chief
Financial Officer, acquired 1,000,000 Ordinary Shares in the Company at a
price of 2.189p per share, Patrick Breen, Chief Commercial Officer and a PDMR,
acquired 509,136 Ordinary Shares in the Company at a price of 2.195p per share
and Tom Lindsay, Non-Executive Director, acquired 222,222 Ordinary Shares in
the Company at a price of 2.25p per share.

 

Following these purchases, Dr Ian Gilham, is interested in 2,505,961 Ordinary
Shares, 0.46% of the issued share capital of the Company, Dr Gino Miele, is
interested in 2,202,187 Ordinary Shares, 0.41% of the issued share capital of
the Company, Russ Shaw is interested in 2,700,000 Ordinary Shares, 0.50% of
the issued share capital of the Company, Patrick Breen is interested in
 509,136 Ordinary Shares, 0.09% of the issued share capital of the Company
and Tom Lindsay is interested in 1,151,605 Ordinary Shares, 0.21% of the
issued share capital of the Company.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

 

 1.                    Details of the person discharging managerial responsibilities / person closely
                       associated
 a.                    Name                                      1.    Dr Ian Gilham

                                                                 2.    Dr Gino Miele

                                                                 3.    Russ Shaw

                                                                 4.    Patrick Breen

                                                                 5.    Tom Lindsay
  2.                   Reason for the notification
 a.                    Position/status                           1.    Non-Executive Chairman

                                                                 2.    Chief Executive Officer

                                                                 3.    Chief Financial Officer

                                                                 4.    Chief Commercial Officer

                                                                 5.    Non-Executive Director
 b.                    Initial notification                      Initial notification

                       /Amendment
 3.                    Details of the issuer, emission allowance market participant, auction
                       platform, auctioneer or auction monitor
 a.                    Name                                      genedrive plc
 b.                    LEI                                       213800ZYODIRZ87Y4K14
 4.                    Details of the transaction(s): section to be repeated for (i) each type of
                       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
                       place where transactions have been conducted
 a.                    Description of the                        Ordinary Shares of 1.5p each

                       Financial instrument, type

                       of instrument

                       Identification code                       GB00B1VKB244
 b.                    Nature of the transaction                 Purchase of ordinary shares
 c.                    Price(s) and volume(s)

Price(s)          Volume(s)

                                                                 1.    2.344p      225,000

                                                                 2.    2.200p      1,135,208

                                                                 3.    2.189p      1,000,000

                                                                 4.    2.195p      509,136

                                                                 5.    2.250p      222,222
 d.                    Aggregated information

                       ·      Aggregated volume                  1.    £5,274.00

                       ·      Price                              2.    £24,974.58

                                                                 3.    £21,890.00

                                                                 4.    £11,175.54

                                                                 5.    £5,000.00

 e.                    Date of the transaction                   20 December 2024
 f.                    Place of the transaction                  London Stock Exchange, AIM Market (XLON)

d.

Aggregated information

·      Aggregated volume

·      Price

 

 

1.    £5,274.00

2.    £24,974.58

3.    £21,890.00

4.    £11,175.54

5.    £5,000.00

 

 

e.

Date of the transaction

20 December 2024

f.

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

 

For further details please contact:

 

 genedrive plc                                     +44 (0)161 989 0245
 Gino Miele: CEO / Russ Shaw: CFO

 Peel Hunt LLP (Nominated Adviser and Broker)      +44 (0)20 7418 8900
 James Steel / Patrick Birkholm

 Walbrook PR Ltd (Media & Investor Relations)      +44 (0)20 7933 8780 or genedrive@walbrookpr.com
                                                   (mailto:genedrive@walbrookpr.com)
 Anna Dunphy                                       +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com). genedrive plc is a
pharmacogenetic testing company developing and commercialising a low cost,
rapid, versatile and simple to use point of need pharmacogenetic platform for
the diagnosis of genetic variants. This helps clinicians to quickly access key
genetic information that will aid them make the right choices over the right
medicine or dosage to use for an effective treatment, particularly important
in time-critical emergency care healthcare paradigms. Based in the UK, the
Company is at the forefront of Point of Care pharmacogenetic testing in
emergency healthcare. Pharmacogenetics informs on how your individual genetics
impact a medicines ability to work for you. Therefore, by using
pharmacogenetics, medicine choices can be personalised, made safer and more
effective. The Company has launched its two flagship products, the Genedrive®
MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and
validated in collaboration with NHS partners and deployed on its point of care
thermocycler platform. Both tests are single-use disposable cartridges which
are ambient temperature stable, circumventing the requirement for cold chain
logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a
worlds-first and allows clinicians to make a decision on antibiotic use in
neonatal intensive care units within 26 minutes, ensuring vital care is
delivered, avoiding adverse effects potentially otherwise encountered and with
no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has
no comparably positioned competitor currently allows clinicians to make a
decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring
that patients who are unlikely to benefit from or suffer adverse effects from
Clopidogrel receive an alternative antiplatelet therapeutic in a timely
manner, ultimately improving outcomes. Both tests have undergone review by the
National Institute for Health and Care Clinical Excellence ("NICE") and have
been recommended for use in the UK NHS.  The Company has a clear commercial
strategy focused on accelerating growth through maximising in-market sales,
geographic and portfolio expansion and strategic M&A, and operates out of
its facilities in Manchester.

 

The Company has a clear commercial strategy focused on accelerating growth
through maximising in-market sales, geographic and portfolio expansion and
strategic M&A, and operates out of its facilities in Manchester.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEAAAEAENLFFA